Business Description
ME Therapeutics Holding Inc
NAICS : 541710
SIC : 3741
ISIN : CA5527671054
Description
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.89 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -86.6 | |||||
3-Year EPS without NRI Growth Rate | -88.2 | |||||
3-Year FCF Growth Rate | -86.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
12-1 Month Momentum % | 0.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.91 | |||||
Quick Ratio | 3.91 | |||||
Cash Ratio | 3.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | 0.08 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -108.31 | |||||
ROA % | -94.14 | |||||
ROIC % | -493.28 | |||||
3-Year ROIIC % | -588.59 | |||||
ROC (Joel Greenblatt) % | -587.33 | |||||
ROCE % | -107.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 108.33 | |||||
Price-to-Tangible-Book | 108.33 | |||||
EV-to-EBIT | -41.31 | |||||
EV-to-EBITDA | -44.78 | |||||
EV-to-FCF | -43.83 | |||||
| Price-to-Net-Current-Asset-Value | 162.5 | |||||
| Price-to-Net-Cash | 162.5 | |||||
Earnings Yield (Greenblatt) % | -2.42 | |||||
FCF Yield % | -2.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:METXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ME Therapeutics Holding Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.028 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 0.09 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR ($) | 0.019904 | ||
| 20-Day SMA ($) | 2.98 | ||
| 12-1 Month Momentum % | 0.09 | ||
| 52-Week Range ($) | 2.9474 - 3.25 | ||
| Shares Outstanding (Mil) | 30.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ME Therapeutics Holding Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ME Therapeutics Holding Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ME Therapeutics Holding Inc Frequently Asked Questions
What is ME Therapeutics Holding Inc(METXF)'s stock price today?
The current price of METXF is $3.25. The 52 week high of METXF is $3.25 and 52 week low is $2.95.
When is next earnings date of ME Therapeutics Holding Inc(METXF)?
The next earnings date of ME Therapeutics Holding Inc(METXF) is .
Does ME Therapeutics Holding Inc(METXF) pay dividends? If so, how much?
ME Therapeutics Holding Inc(METXF) does not pay dividend.
Press Release
Articles on ME Therapeutics Holding Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers